The subgroups of patients selected according to genetic data did not differ significantly in terms of these factors, except for significant differences in the proportion of patients using and not using menopausal hormonal therapy (MHT) de-pending on the 5-HTT genotype, and significant differences in the proportion of patients with ovarian cancer and endometrial cancer depending on the MAO-A genotype (Table 1). This evidence concerns the gene MAOA and ovarian cancer.